Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Vivus officially names ex-AstraZeneca exec Zook as new CEO

The dust is settling over at Vivus after an intense proxy fight that top shareholder First Manhattan Co. waged for months leading up to last week's shareholder meeting. But now, having gotten what it wished for--control of the company's board--the new management is moving in and moving fast.

Roche casts its net (again) for the perfect chairman

Roche needs a new chairman, and the candidates aren't exactly lining up. With its top two choices having already declined the position, the Swiss drug giant may have to turn to an outsider to succeed 16-year vet and former CEO Franz Humer.

Does Roche need a biotech brain in the chairman's office?

It looks like Roche's top two picks for the role of chairman--both execs from the multinational field--have taken a pass on the job. And that has left at least a couple of prominent biotech vets in the mix of possible candidates.

AstraZeneca's CFO Simon Lowth leaves for BG Group

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Vivus hands control to rebel investors, with new CEO ready to step in

Under the deal, which has to be approved by shareholders, the board of directors will expand to 11 members from 9. Vivus will retain four board seats and FMC's nominees will take 6. Former AstraZeneca exec Tony Zook, backed by FMC, is expected to round out the board, taking the place of current CEO Leland Wilson.

UPDATED: Vivus and First Manhattan reach settlement to close out proxy war

The agreement will expand  the board to 11 members from 9, with First Manhattan installing 6 directors as four Vivus directors step down. F ormer AstraZeneca  exec Tony Zook, backed by FMC, is expected to round out the board, taking the place of current CEO Leland Wilson.

AstraZeneca CFO jumps ship in latest executive switcheroo

The executive suite at AstraZeneca is churning again. CFO Simon Lowth is jumping ship for BG Group, a natural gas company. He'll be around till the end of October, however, giving CEO Pascal Soriot time to bring in a successor.

Dunsire makes quick leap from Millennium to fast-growing EnVivo

Just two months after abruptly leaving Millennium as Takeda prepared to absorb its R&D work in its global research group and eliminate her position, Dunsire has been tapped as the new CEO at EnVivo Pharmaceuticals, a fast-growing drug developer in Watertown, MA focused on a late-stage CNS program for Alzheimer's and schizophrenia.

Harvard chemist takes CEO job at Warp Drive

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Biogen R&D exec Gilman hits the exit door

A little more than a year after rejoining Biogen Idec ($BIIB) as head of early-stage research, Michael Gilman is a free agent. Gilman left his position as executive vice president of research at Biogen back in 2005 to set up Stromedix, a biotech working on a new fibrosis treatment in-licensed from Biogen.